Drug intelligence / Profile preview

sctv01c

Development stage: Phase 3
Lead developer: Sinocelltech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SCTV01C is a bivalent recombinant trimeric spike protein subunit vaccine developed by Sinocelltech for the prevention of COVID-19. It targets the spike protein ectodomain sequences of both the Alpha (B.1.1.7) and Beta (B.1.351) SARS-CoV-2 variants, aiming to induce broad immune responses against multiple circulating strains[4][9][10]. The vaccine is administered via intramuscular injection and has been evaluated in clinical trials as a booster for individuals previously vaccinated with mRNA COVID-19 vaccines[3][6]. SCTV01C has demonstrated safety and immunogenicity in healthy adults, with robust cross-neutralizing antibody responses against Delta and Omicron variants following heterologous boosting[6].

Targets

BVDV E2 (Bovine viral diarrhea virus glycoprotein E2)

Beyond the preview

Go deeper on sctv01c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sctv01c.

Explore the full profile